Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Treatment and Management of Schizophrenia in Europe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of schizophrenia as defined by DSM-IV-R as determined by the M.I.N.I.plus~2. Age 18 or older.~3. The first psychosis occurred at least one year and no more than 7 years ago.\*~4. If patients are using an antipsychotic drug, a medication switch is currently under consideration.~5. Capable of providing written informed consent.~Exclusion Criteria:~1. Intolerance / hypersensitivity to one of the drugs (including active substances, metabolites and excipients) in this study including oral risperidone, paliperidone and aripiprazole and/or hypersensitivity to risperidone.~2. Pregnancy or lactation.~3. Patients who are currently using clozapine.~4. Patients who do not fully comprehend the purpose or are not competent to make a rational decision whether or not to participate.~5. Patients with a documented history of non-response and/or intolerance to any of the study medications and/or a documented history of non-response to a treatment with one of the study drugs of at least 6 weeks within the registered dose range.~6. Forensic patients.~7. Patients who have been treated with an investigational drug within 30 days prior to screening.~8. Simultaneous participation in another intervention study (neither medication or psychosocial intervention).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Phase I: 1 arm 'amisulpride open label' (Type: OTHER): For 4 weeks, all patients will be treated with amisulpride open label.
- Phase II: 'amisulpride double blind' (Type: ACTIVE_COMPARATOR): Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
- Phase II 'olanzapine double blind' (Type: ACTIVE_COMPARATOR): Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
- Phase III: 1 arm 'clozapine open label' (Type: OTHER): Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
- Psychosocial intervention (Type: EXPERIMENTAL): Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
- Psychosocial Intervention phase: 'TAU' (Type: NO_INTERVENTION): Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete